A Randomized Controlled Study on the Clinical Efficacy of Ginkgo Biloba Combined with Nicorandil in Patients with HFmrEF.

Abstract

This study aimed to explore the clinical efficacy of Ginkgo biloba combined with Nicorandil in patients with heart failure who have a mild decrease in ejection fraction (HFmrEF).A total of 316 patients with HFmrEF were selected and randomly assigned to either a control group or a combination of the Ginkgo biloba and Nicorandil group, each group consisting of 158 patients. The control group received standard secondary preventive treatment, while patients in the combination group received oral Ginkgo biloba and Nicorandil based on stable conventional treatment. Both groups were treated continuously for six months. The age, sex, body mass index (BMI), New York Heart Association cardiac function classification, history of coronary heart disease, hypertension, diabetes, atrial fibrillation, smoking, left ventricular ejection fractions (LVEF), heart rate, glycosylated hemoglobin (HbA1c), and combined drug use of the patients in the two groups were recorded. The efficacy endpoints were BMI, heart rate, blood lipid levels, fasting blood glucose, renal function, HbA1c, N-terminal pro-brain natriuretic peptide (NT-proBNP), LVEF, cardiopulmonary exercise testing parameters, 6-minute walking distance (6MWD), and the Kansas City Cardiomyopathy Questionnaire (KCCQ) score after six months of treatment. The incidence of adverse reactions in the two groups was recorded.After six months of treatment, the BMI, heart rate, NT-proBNP, low-density lipoprotein cholesterol, triglyceride, creatinine, fasting blood glucose, and HbA1c levels of patients in the Ginkgo biloba combined with Nicorandil group were lower than those in the control group (P < 0.05). The LVEF, high-density lipoprotein cholesterol, VO2peak, oxygen uptake efficiency slope, 6MWD, and KCCQ scores were higher in the Ginkgo biloba combined with Nicorandil group than in the control group (P < 0.05). There was no statistically significant difference between the two groups of patients (P > 0.05) in the incidence of hypotension, hypoglycemia, hypokalemia, headache, and hospitalization due to worsening heart failure.Ginkgo biloba combined with Nicorandil can effectively improve heart function, blood lipid levels, blood glucose levels, renal function, exercise tolerance, and health-related quality of life in patients with HFmrEF. Because there were no significant adverse reactions, they can be safely used.